Federal Register / Vol. 87, No. 68 / Friday, April 8, 2022 / Notices 20863 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The Division of Healthcare Quality 

Promotion’s Project Firstline (PFL) is 

submitting a new information collection 

request to cover two partner reporting 

tools for three years. PFL aims to 

provide frontline healthcare personnel 

(HCP) necessary infection prevention 

and control (IPC) knowledge to prevent 

the transmission of healthcare acquired 

infections and COVID–19 in healthcare 

settings. IPC materials and education 

will be disseminated by CDC and 

funded partners via trainings and 

promotional materials to reach 

healthcare personnel in a variety of 

settings. 

PFL is a new program, and as such, 

collection of performance/progress data 

is critical for successful program 

implementation and ongoing 

improvement. Gathering data from PFL 

partners will provide crucial insights 

into the diverse needs of HCP, gaps in 

existing CDC training resources, and 

will help CDC understand the reach and 

impact of the PFL initiative. Having this 

information will allow CDC and 

partners to monitor progress towards 

desired outcomes while improving PFL 

outreach and programming based on 

lessons learned. The PFL collaborative 

network, data-driven training and 

education programs, and targeted 

messaging through digital platforms will 

help drive behavior change—enhancing 

the readiness of the nation’s frontlines 

to respond to the current COVID–19 

pandemic and future disease outbreaks. 

The PFL collaborative consists of 11 

national partners (five of which have 

subrecipients). National partners and 

their subrecipients will report on their 

communications and training efforts 

conducted with, or tailored to, their 

respective memberships under the PFL 

initiative. CDC requests OMB approval 

for an estimated 1,168 annual burden 

hours. There is no cost to respondents 

other than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

National Partners .............................. Comms Reporting ............................ 11 12 1.0 132 

National Partners .............................. Training Reporting ............................ 11 12 0.2 22 

Subrecipients & Collaborators .......... Comms Reporting ............................ 74 12 1.0 888 

Subrecipients & Collaborators .......... Training Reporting ............................ 63 12 0.2 126 

Total ........................................... ........................................................... ........................ ........................ ........................ 1,168 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–07520 Filed 4–7–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–22–1254] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled Communities 

Organized to Prevent Arboviruses: 

Assessment of Knowledge, Attitudes, 

and Vector Control Practices and SeroPrevalence and Incidence of Arboviral 

Infection in Ponce, Puerto Rico (COPA 

Study), to the Office of Management and 

Budget (OMB) for review and approval. 

CDC previously published a ‘‘Proposed 

Data Collection Submitted for Public 

Comment and Recommendations’’ 

notice on [insert November 22, 2021] to 

obtain comments from the public and 

affected agencies. CDC did not receive 

comments related to the previous 

notice. This notice serves to allow an 

additional 30 days for public and 

affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Communities Organized to Prevent 

Arboviruses: Assessment of Knowledge, 

Attitudes, and Vector Control Practices 

and Sero-Prevalence and Incidence of 

Arboviral Infection in Ponce, Puerto 

Rico (COPA Study) (OMB Control No. 

0920–1254)—Reinstatement with 

Change—National Center for Emerging 

and Zoonotic Infectious Diseases 

(NCEZID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The four viruses that cause dengue are 

transmitted by Aedes species 


jspears on DSK121TN23PROD with NOTICES1
20864 Federal Register / Vol. 87, No. 68 / Friday, April 8, 2022 / Notices 

mosquitoes and were introduced to the 

Americas over the past several hundred 

years where they have since become 

endemic. Puerto Rico, a Caribbean 

island and U.S. commonwealth, has the 

highest burden of dengue virus in the 

U.S., and recent years have seen the 

emergence of two epidemic arthropodborne viruses (arboviruses) also 

transmitted by Aedes mosquitoes. 

Chikungunya virus was introduced into 

the Caribbean in late 2013 and caused 

large epidemics of fever with severe 

joint pain throughout the Caribbean and 

Americas in 2014. Zika virus, the first 

arbovirus that can also be transmitted 

through sexual contact, was first 

detected in the Americas in 2014 and 

has been associated with devastating 

birth defects and Guillain-Barre 

syndrome. Yellow fever virus has 

recently caused large outbreaks in 

Brazil, and there is risk of importation 

to Puerto Rico and other counties in the 

Americas. 

The public health response to the 

spread of these arboviruses throughout 

the tropics, where their mosquito 

vectors thrive, has been hampered by a 

lack of sustainable and effective 

interventions to prevent infection with 

any of these arboviruses at the 

community level. Moreover, the rapid 

speed with which new arboviruses 

spread generally does not provide the 

time needed to plan and implement 

community-level interventions to 

decrease viral transmission. Although 

several candidate vaccines for 

chikungunya and Zika viruses are 

currently in clinical development, none 

are yet available. A dengue vaccine was 

recently recommended for children 

9–16 years old with previous dengue 

infection and living in dengue-endemic 

parts of the United States. However, this 

will only benefit a small proportion of 

the population at risk for dengue 

infection. 

The purpose of the Communities 

Organized to Prevent Arboviruses 

(COPA) project is to measure the 

incidence of arboviral infections and 

assess suitability, acceptability, and 

impact of community-level mosquito 

control interventions in 38 communities 

in southern Puerto Rico. The study 

investigators have prior experience 

working in these communities; 

however, there is minimal available 

information regarding the prevalence or 

incidence of infection with tropical 

arboviruses, density of Ae. aegypti 

mosquitos, and community members’ 

knowledge, attitudes, and behaviors for 

avoiding mosquito bites. This 

information is needed to inform 

decision-making regarding the location, 

design, and content of mosquito control 

interventions to be implemented, as 

well as to evaluate their effectiveness in 

reducing the arbovirus burden. 

Additionally, the COPA project can act 

as a research platform to assess 

acceptability of arbovirus vaccines and 

other individual level prevention 

measures in Puerto Rico and provide 

community-level data on emerging 

diseases, including novel coronavirus 

2019 (COVID–19). 

We will collect demographic 

information (e.g., age, sex, duration of 

time residing in Puerto Rico), travel 

history, and information on recent 

illnesses from all participants via 

household (and individual) 

questionnaires. Parents or guardians 

will serve as proxy respondents for 

children aged <7 years. The 

questionnaires will be administered 

after written consent and written or 

verbal assent (for minors) from those 

present in the household at the time of 

the visit. GPS coordinates will also be 

collected for each household visited to 

later assess for potential clustering of 

arboviral infections within 

communities. We will ask participants if 

they have been ill with arbovirus- or 

COVID–19-like illness (i.e., fever, rash, 

cough, sore throat, difficulty breathing, 

diarrhea, body pain, or loss of taste/ 

smell) in the past week and year. If so, 

we will collect details on the symptoms 

experienced during their illness. 

Questionnaire administration and study 

participation will be limited to residents 

from the 38 communities in Ponce. 

Being a resident is defined by having 

slept in the house for at least four of the 

past seven nights. At the time of the 

questionnaire administration, ∼15 mL of 

blood will be collected to conduct 

serological testing of arboviruses for a 

sero-survey. If the participant has 

COVID–19-like symptoms, an anterior 

nasal swab will also be collected. 

The questionnaire section will vary 

depending on the age of each 

participant. The Household 

questionnaire will be administered to 

one household representative in each 

home with one or more COPA 

participants. This questionnaire collects 

information on household composition, 

characteristics, and use of chemical 

insecticides and other preventive 

practices. The household representative 

should be 21 years or older or an 

emancipated minor. If all eligible 

household members are unemancipated 

minors, a household member over the 

age of 50 may act as household 

representative and complete this section 

of the survey only. A minor residing 

without an adult in the household may 

participate and act as a household 

representative if they have parent or 

legal guardian consent to do so. 

The Individual questionnaire will be 

administered to all participants to 

collect individual-level sociodemographic information. This 

questionnaire will collect information 

on past illnesses and health seeking 

behaviors, identify the main healthcare 

facilities used in the area, and estimate 

costs associated with acute febrile 

illness. Questions related to COVID–19 

vaccine uptake, illness, and diagnosis 

are also included to describe and 

estimate the number of previous SARS– 

CoV–2 infections and evaluate the 

success of ongoing COVID–19 

vaccination efforts in these 

communities. 

The mobility questionnaire will be 

administered to all participants to assess 

general individual-level mobility 

patterns, including time spent in and 

outside of the home each week. We will 

ask participants about the location and 

characteristics of places where they 

spend more than five hours a week to 

assess potential arboviral exposures 

outside of the home. 

The assessment of Knowledge, 

Attitudes, and Practices (KAP) 

questionnaire will be administered to 

participants 14–50 years old to collect 

information on knowledge, perceptions 

of risk and prevention measures, and 

experience with dengue and COVID–19. 

This data will be used to understand 

how community members view 

arboviral diseases and COVID–19 and 

how these perceptions relate to 

experience and willingness to adopt 

individual and community-level 

prevention measures. Questions related 

to general perceptions and confidence 

in vaccines will be asked to see how 

these relate to intentions to vaccinate 

against dengue and COVID–19. 

A Vector Control questionnaire will 

be administered to all household 

representatives to evaluate knowledge 

and acceptability of several mosquito 

control methods. This information will 

be shared with local governments and 

vector control agencies to inform 

selection and implementation of 

potential mosquito control interventions 

in the region. 

An Acute Illness Surveillance (AIS) 

project component is being 

implemented to better identify and 

assess the incidence of arboviral disease 

and COVID–19 among COPA 

participants. This additional weekly 

activity will use an automated textmessaging system to ask COPA 

household representatives and other 

household adults who consent to 

receive text messages if any COPA 

participants in the household have 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 68 / Friday, April 8, 2022 / Notices 20865 

experienced fever or other COVID-like 

symptoms in the past seven days. 

Project staff will contact households in 

which one or more participants reported 

symptoms to schedule an appointment 

to collect samples for arbovirus and 

SARS–CoV–2 molecular testing and to 

administer a AIS questionnaire about 

symptoms, exposure and health seeking 

behaviors. From previous febrile 

surveillance studies, we expect 

approximately 40% of household adults 

will respond to text messages each week 

and 10% of COPA participants will 

report acute symptoms and agree to a 

sample collection visit each year. 

Participants with a positive SARS– 

CoV–2 molecular test will be contacted 

by phone 2–4 weeks later for a COVID– 

19 Case Follow-Up questionnaire on 

symptoms, health care seeking, 

potential exposures, and outcomes of 

SARS–CoV–2 infection. We are 

expecting that 20% of participants who 

report symptoms will have a positive 

COVID–19 result and respond to this 

follow-up questionnaire. 

The central COPA questionnaires 

(Household, Individual, KAP, Mobility, 

and Vector Control) will be repeated 

among approximately 3,800 participants 

every 12 months, up to a period of five 

years. The AIS and COVID–19 FollowUp components will be renewed and 

modified annually as applicable 

according to research and funding 

priorities. This project will allow us to 

better understand the risk, perceptions, 

and burden of arboviral infections and 

COVID–19 and evaluate a communitybased approach for vector control in 38 

communities in Ponce, Puerto Rico. The 

information obtained will inform 

decision making regarding the location, 

design, content, and evaluation of future 

mosquito control interventions 

implemented in Puerto Rico. Data on 

incidence and perception of COVID–19 

disease will also be used to inform local 

control programs and fill the current 

knowledge gaps. 

CDC requests OMB approval for an 

estimated 4,309 annual burden hours. 

There is no cost to respondents other 

than the time needed to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Ponce residents from the 38 selected communities 21 years and older or emancipated minor.Household Representative questionnaire ...... 2,700 1 10/60 

Ponce residents from the 38 selected communities 1–50 years old.Individual questionnaire ................................. 3,800 1 20/60 

Ponce residents from the 38 selected communities 1–50 years old.Specimen collection ....................................... 3,800 1 5/60 

Ponce residents from the 38 selected communities 14–50 years old.Knowledge, Attitudes, and Practices questionnaire.3,090 1 15/60 

Ponce residents from the 38 selected communities 1–50 years old.Mobility questionnaire .................................... 3,800 1 10/60 

Ponce residents from the 38 selected communities 21 years and older.Vector Control questionnaire ......................... 2,500 1 10/60 

Ponce residents from the 38 selected communities 21 years and older.AIS text message ........................................... 1,000 52 0.5/60 

Ponce residents from the 38 selected communities with inclusion criteria.AIS questionnaire ........................................... 380 1 8/60 

Ponce residents from the 38 selected communities with inclusion criteria that tested 

positive for SAR–CoV–2.

COVID–19 Case Follow-Up questionnaire .... 75 1 6/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–07519 Filed 4–7–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund 

Ministerio de Salud de la Repu ́blica de 

Panama ́ (MINSA) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

cancellation of an award of 

approximately $10,000,000 for Year 1 of 

funding to MINSA. 

DATES: The notice of award was 

cancelled on 04/05/2022. 

FOR FURTHER INFORMATION CONTACT: Lily 

de Leon, Center for Global Health, 

Centers for Disease Control and 

Prevention, 18 Avenida 11–37, Zona 15, 

VHIII, 502) 23298426 or (404) 718–2645 

USA. Email: izo0@cdc.gov. 

SUPPLEMENTARY INFORMATION: On March 

9, 2022, CDC announced a single-source 

award to support MINSA to scale up 

high-impact HIV prevention, testing and 

treatment models in Panama. This 

award is cancelled in its entirety. 

Dated: April 5, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–07542 Filed 4–7–22; 8:45 am] 

BILLING CODE 4163–18–P 


jspears on DSK121TN23PROD with NOTICES1